Family Disclosure of a Cancer Diagnosis to Patients - Top-Institutions - MDSpire

Family Disclosure of a Cancer Diagnosis to Patients

  • By

  • Chenglei Hu

  • Hongyu Zhao

  • Yanhong Yan

  • Fang Fang

  • Chen Chen

  • Ping Yu

  • Jinrong Wei

  • Ericka Waidley

  • Josephine Hegarty

  • Pingting Zhu

  • April 30, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology
    • Palliative Care
    • Medical Ethics

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology
    • Psychosocial Oncology
    • Bioethics

  • #3

    National Cancer Center China
    National Cancer Center China

    Beijing, N/A

    Key Differentiators

    • Oncology
    • Cultural Medicine
    • Health Communication

  • #4

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Oncology
    • Medical Ethics
    • Health Communication

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Oncology
    • Palliative Care
    • Cultural Competency

Original Source(s)

Family Disclosure of a Cancer Diagnosis to Patients

  • by Chenglei Hu, Hongyu Zhao, Yanhong Yan, Fang Fang, Chen Chen, Ping Yu, Jinrong Wei, Ericka Waidley, Josephine Hegarty, Pingting Zhu

  • April 30, 2026

Related Content

Emerging applications of artificial intelligence for risk stratification in head and neck cancer: a scoping review

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma

Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort